Why are drug companies racing to develop noncannabis endocannabinoid meds?

Endocannabinoid drug research is booming, but why?

An early stage drug trial of an experimental medication meant to act on the body’s endocannabinoid system ended in disaster last week after the drug left one person dead and five others seriously ill.

The drug in question contained no cannabis or cannabis derivatives, contrary to what initial reports indicated, but was actually a chemically created FAAH inhibitor designed to tap into the body’s endocannabinoid system.

Cannabinoid receptors are found throughout the human body and allow communication and coordination between different cell types, according to the National Organization for the Reform of Marijuana Laws (NORML).

The endocannabinoid system has been tied to a growing number of bodily functions, according to the U.S. Department of Health and Human Services (HHS).

Thus, harnessing and modulating endocannabinoid activity may hold therapeutic promise for a wide range of diseases and health conditions...

Rate this article: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.